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Abstract
PINK1 and Parkin mutations cause recessive Parkinson’s disease (PD). In Drosophila and SH-SY5Y cells, Parkin is recruited by
PINK1 to damaged mitochondria, where it ubiquitinates Mitofusins and consequently promotes mitochondrial fission and
mitophagy. Here, we investigated the impact of mutations in endogenous PINK1 and Parkin on the ubiquitination of
mitochondrial fusion and fission factors and the mitochondrial network structure. Treating control fibroblasts with
mitochondrial membrane potential (Dy) inhibitors or H2O2 resulted in ubiquitination of Mfn1/2 but not of OPA1 or Fis1.
Ubiquitination of Mitofusins through the PINK1/Parkin pathway was observed within 1 h of treatment. Upon combined
inhibition of Dy and the ubiquitin proteasome system (UPS), no ubiquitination of Mitofusins was detected. Regarding
morphological changes, we observed a trend towards increased mitochondrial branching in PD patient cells upon
mitochondrial stress. For the first time in PD patient-derived cells, we demonstrate that mutations in PINK1 and Parkin
impair ubiquitination of Mitofusins. In the presence of UPS inhibitors, ubiquitinated Mitofusin is deubiquitinated by the UPS
but not degraded, suggesting that the UPS is involved in Mitofusin degradation.
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder, clinically characterized by bradykinesia, tremor, and
rigidity, with a monogenic cause in about 2–3% of the cases [1].
Studying the consequences of mutations in recessively inherited
PD-associated genes, such as PTEN-induced putative kinase 1 (PINK1)
or the E3 ubiquitin ligase Parkin, may help to understand the
mechanisms underlying the disease also in sporadic, idiopathic PD
patients.
Although the exact cause of sporadic PD is still elusive,
mitochondrial dysfunction has long been connected with the
disease. Impaired respiratory chain function has been found in
sporadic PD patients and different PINK1 or Parkin knockdown
models [2,3,4,5]. Furthermore, Drosophila pink1 and parkin loss-of-
function mutants showed defects in mitochondrial morphology
[6,7,8,9,10]. Transgenic expression of parkin markedly ameliorated
all pink1 loss-of-function phenotypes, but not vice versa, suggesting
that parkin functions downstream of pink1 [6,7,8].
A series of experiments in Drosophila, SH-SY5Y cells, and
primary mouse neurons provided evidence that the PINK1/
Parkin pathway promotes mitochondrial fission and that loss of
activity of either protein results in decreased fission and impaired
tissue integrity [11,12]. Inactivation of the dynamin-related
protein 1 (drp1), a key factor of mitochondrial fission, enhances
the pink1 and parkin-mutant phenotypes in Drosophila [11,12,13]. By
contrast, increased drp1 gene dosage or inactivation of the
mitochondrial fusion-promoting components optic atrophy 1 (opa1)
and mitofusin (mfn) suppress the mitochondrial phenotype in
Drosophila pink1 and parkin mutants [11,12,13]. Recently, these
observations have been linked to mitophagy. Under stress
conditions, PINK1 recruits Parkin to dysfunctional mitochondria
[14,15,16,17]. The subsequent ubiquitination of Mitofusins by
Parkin inhibits mitochondrial fusion and thus promotes mito-
chondrial fragmentation as an initial step of mitophagy [18,19,20].
In PD patient fibroblasts, only the morphological effects of
mutations in Parkin have been studied so far revealing that the
degree of mitochondrial branching was higher than in controls
[21].
In our present work, we used fibroblast cultures from PD
patients carrying two mutated Parkin or PINK1 alleles to investigate
the consequences of mutations in endogenous PINK1 and Parkin
on the ubiquitination of mitochondrial fusion and fission factors.
Furthermore, we evaluated the influence of these mutations on the
structure of the mitochondrial network in human cells.
Results
Two fibroblast cultures with homozygous PINK1 mutations,
p.Q456X or p.V170G, two cultures with homozygous Parkin
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two age-matched mutation-negative healthy controls were includ-
ed in the study. The effects of these mutations on PINK1 and Parkin
mRNA levels are described elsewhere [16,22]. Clinical features of
the mutation carriers were compatible with idiopathic PD, with
the exception of an earlier age of onset of 42.3+/213.5 years
[23,24,25]. All experiments were performed at least in triplicate
and representative blots are shown.
Decreased Mfn2 levels after valinomycin or CCCP
treatment in control fibroblasts
First, we determined the endogenous levels of Mfn2 in the
PINK1 and Parkin mutants and controls under basal conditions and
after exposure to 1 mM valinomycin for 12 h. This treatment
caused a drop in the protein levels of Mfn2 in controls but not in
either of the mutant cells (Figure 1A). Furthermore in controls,
Mfn2 had an additional band on the Western blot, which was
about 8 kDa larger in size than the non-modified form, consistent
with monoubiquitination of the protein. By contrast, protein levels
of OPA1 and Fis1 were unchanged in all cell cultures when
incubated with valinomycin (Figure 1B) and modified forms of
these proteins were not detectable. Protein levels of the
mitochondrial marker voltage-dependent anion channel 1
(VDAC1) were comparable in all samples under basal and stress
conditions (Figure 1A, B).
To test whether the used Mfn2 antibody specifically binds
Mfn2, a knock-down experiment with siRNA against Mfn1 or
Mfn2 was performed (Figure 1C). This experiment showed a drop
in Mfn2 level only when siRNA against Mfn2 was employed,
confirming the specificity of the antibody.
In this experiment also the Mfn2 homolog mitofusin 1 (Mfn1)
[26] was investigated and showed comparable effects (Figure S1).
Since the available Mfn1 antibody was less sensitive than the Mfn2
antibody, out of the series of experiments for Mfn2 described in
this article, only selected ones were repeated for Mfn1 (see
supplementary material).
Reduced Mfn2 levels in controls but not in PINK1- and Parkin-
mutant fibroblasts were also detected after incubation with the
protonophore cyanide m-chlorophenylhydrazone (CCCP; 10 mM
for 12 h) (Figure S2). Since valinomycin and CCCP had identical
effects on Mfn2, only results from the experiments using
valinomycin are shown.
Figure 1. Expression of mitochondrial fusion and fission proteins after valinomycin treatment. Fibroblasts from a healthy control, a
homozygous PINK1 mutant and a homozygous Parkin mutant were cultured under basal conditions or treated with 1 mM valinomycin for 12 h. The
protein levels of (A) Mfn2, (B) OPA1 and Fis1 were investigated by means of Western blotting. Valinomycin exposure caused a decrease in Mfn2 levels
in controls, but not in PINK1-o rParkin-mutant cells. The protein levels of OPA1 and Fis1 were not influenced by this treatment in any of the cell
cultures. Under basal and stress conditions, expression of the mitochondrial marker VDAC1 was comparable in mutants and controls. (C) Mutant cells
were incubated with scrambled siRNA, Mfn1 siRNA, Mfn2 siRNA or a combination of Mfn1 and Mfn2 siRNA for 40 h. Western blot analysis was
performed with an antibody against Mfn2. The Mfn2 level decreased only when Mfn2 siRNA was employed, confirming the specificity of the anti-Mfn1
antibody used in our study. b-actin served as a loading control. Fis1 – fission 1; Mfn1 – mitofusin 1; Mfn2 – mitofusin 2; OPA1 – optic atrophy 1;
VDAC1 – voltage-dependent anion channel 1.
doi:10.1371/journal.pone.0016746.g001
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valinomycin exposure and is detected in the
mitochondrial fraction
Next, we intended to verify whether the additional band on the
Mfn2 blot, which is present only in controls after valinomycin- or
CCCP-induced stress, is indeed explained by ubiquitination of the
protein. For this, we performed immunoprecipitation using an
antibody against Mfn2. Whole cell lysates from non-treated and
valinomycin-treated (1 mM, for 6 h) controls were employed. The
resulting immunoprecipitates were analyzed by Western blotting
with an antibody against ubiquitin (Figure 2, left panel) or with an
antibody against Mfn2 (Figure 2, right panel). On both blots,
bands of the size of mono- and polyubiquitinated or multiple
monoubiquitinated Mfn2 were only detected in valinomycin-
treated but not in non-treated controls. Immunoprecipitation was
also performed with cell lysates from valinomycin-treated PINK1-
and Parkin-mutant fibroblasts. Western blot analysis with an Mfn2
antibody showed only the non-modified form of the protein
(Figure S3). Taken together, these findings supported our previous
results and underline that Mfn2 is ubiquitinated via the PINK1/
Parkin pathway.
To determine the subcellular localization of ubiquitinated Mfn1
and 2 in control fibroblasts, cells were incubated with 1 mM
valinomycin for 6 h and mitochondrial and cytosolic protein
fractions separated. Western blot analysis revealed that Mfn1/2
and their ubiquitinated forms are exclusively localized in the
mitochondrial fraction (Figure 3 and Figure S4). The same
findings for Mfn2 were obtained when the fractionation
experiment was repeated in SH-SY5Y cells (Figure S5).
Rescue of Mfn2 ubiquitination in mutant fibroblasts
To test whether lack of ubiquitination of Mfn2 in the mutants can
be rescued, we transfected control, PINK1- and Parkin-mutant
fibroblasts with an empty vector, a vector containing PINK1-V5 or a
vector containing FLAG-Parkin. Twenty-four hours after transfec-
tion, these cells were cultured under basal conditions or treated with
1 mM valinomycin for an additional 12 h. Whole cell lysates were
analyzed by Western blotting. Using antibodies against V5 and
Figure 2. Ubiquitination of Mfn2 upon valinomycin treatment. Fibroblasts from a healthy control were treated with 1 mM valinomycin for
6 h. Whole cell lysates from non-treated and valinomycin treated controls were immunoprecipitated using an antibody against Mfn2.
Immunoprecipitates were analyzed by Western blotting using an antibody against ubiquitin (left panel). Subsequently, the membrane was washed
and reprobed with an antibody against Mfn2 (right panel). Ubiquitinated forms of Mfn2 (mono- and polyubiquitinated) are present only in
valinomycin treated controls. Mfn2 – mitofusin 2; Ub-Mfn2 – ubiquitinated mitofusin 2.
doi:10.1371/journal.pone.0016746.g002
Figure 3. Mitochondrial localization of ubiquitinated Mfn2 after valinomycin treatment. Control fibroblasts were cultured under basal
conditions or treated with 1 mM valinomycin for 6 h. Cells were harvested and mitochondrial and cytosolic fractions were analyzed by Western
blotting. The subcellular localization of Mfn2 was determined. Quality of cellular fractionation was confirmed using antibodies against VDAC1 and b-
actin. The ubiquitinated forms of Mfn2, which were observed only after valinomycin stress, are exclusively found in the mitochondrial fraction. A
longer exposure of the blot showed several Mfn2 bands with higher molecular weight, indicative of Mfn2 polyubiquitination (enlarged cutout). Cyt –
cytosolic fraction; Mit – mitochondrial fraction; Mfn2 – mitofusin 2; VDAC1 – voltage-dependent anion channel 1.
doi:10.1371/journal.pone.0016746.g003
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Parkin were detected, confirming successful transfection (Figure 4,
upper panel). Furthermore, using an antibody against Mfn2,
ubiquitinated Mfn2 was detected in control cells under stress
conditions (Figure 4A). In PINK1-mutant cells, ubiquitination of
Mfn2 under stress was rescued through expression of PINK1-V5 but
not through expression of FLAG-Parkin (Figure 4B). Similarly, in
Parkin-mutant fibroblasts, ubiquitinated Mfn2 was only detected
after transfection with FLAG-Parkin (Figure 4C).
Ubiquitination of Mfn2 occurs within 1 h of valinomycin
treatment and is prevented in the presence of
epoxomicin
To explore whether the ubiquitinated forms of Mfn2 are
degraded by the UPS, we treated control (Figure 5A), PINK1-
(Figure 5B) and Parkin-mutant (Figure 5C) fibroblasts with 1 mM
valinomycin alone (Figure 5, left panel) or in combination with
10 mM epoxomicin (Figure 5, right panel) and extracted proteins
at different time points for Western blot analysis. In control cells,
valinomycin treatment initiated the ubiquitination of Mfn2 within
1 h of incubation (Figure 5A, left panel). Mfn2 ubiquitination was
prevented by simultaneous exposure to epoxomicin (Figure 5A,
right panel). The same effect was observed with MG132 (Figure
S6). By contrast, simultaneous treatment with valinomycin and the
lysosomal inhibitor bafilomycin did not prevent Mfn2 ubiquitina-
tion in control cells (Figure 6). To exclude that proteasomal
inhibition influences the effect of the potassium ionophore
valinomycin, the mitochondrial membrane potential in control
fibroblasts was monitored during 9 h of treatment with valino-
mycin alone or in combination with epoxomicin. Both culturing
conditions caused a similar drop in membrane potential (Figure
S7). The protein levels of non-modified Mfn2 remained
unchanged in all samples over time when treated with valinomycin
plus epoxomicin (Figure 5, right panel). To further test whether
epoxomicin alone has an impact on the protein levels of Mfn2, we
treated control cells with 10 mM epoxomicin but observed no
change in Mfn2 levels during 9 h of incubation (Figure S8).
Next, we wanted to show that inhibition of the UPS is not only
preventingubiquitination ofMfn1 andMfn2(asshown above)butis
actually causing deubiquitination of already ubiquitinated Mitofu-
sins. For that we treated control fibroblasts with valinomycin to
induce ubiquitination. After 6 h we added MG132 or DMSO
(dissolvent for MG132) and harvested cells at different time points.
Western blot analysis revealed that upon 6 h of UPS inhibition,
levels of non-modified Mitofusins were almost at the same level as
before treatment (Figure 7).This additionally confirms that the UPS
is involved in the processing of ubiquitinated Mfn1 and Mfn2.
Exposure to H2O2 causes ubiquitination of Mfn2
Next, we investigated whether exposure of control fibroblasts to
the superoxide generator H2O2 also results in ubiquitination of
Mfn2. Therefore, cells were incubated with 100 mMH 2O2 for 12 h
and compared to cells stressed with 1 mM valinomycin for 6 h and
non-treated cells. Mitochondrial and cytosolic fractions of these
cells were analyzed by Western blotting using antibodies against
Mfn2, Parkin, VDAC1 and b-actin. The predominant presence of
VDAC1 in the mitochondrial and of b-actin in the cytosolic
fraction indicated good quality of the fractionation (Figure 8A).
Densitometric analysis revealed a significant drop in protein levels
of non-modified Mfn2 in the mitochondrial fraction after
valinomycin but also after H2O2 treatment (Figure 8A and B).
Under both stress conditions, high-molecular-weight bands of
Mfn2 were detected, indicative of Mfn2 ubiquitination. As already
demonstrated in our recently published study on PINK1- and
Parkin-mutant fibroblasts [16], both treatments caused a significant
drop in protein levels of Parkin in the cytosolic fraction (Figure 8A
and C). Longer exposure of the Western blots revealed mitochon-
drial translocation of endogenous Parkin after both treatments
(Figure 8A, right panel).
Branching of the mitochondrial network
Finally, we determined the impact of the absence of Mfn2
ubiquitination in the mutants under stress conditions on the
mitochondrial network. To evaluate the degree of mitochondrial
branching, we measured the form factor [21] in cells from a PINK1
mutant, a Parkin mutant and a control. This showed a comparable
degree of mitochondrial network branching in all investigated
individuals under basal conditions. When we stressed the cells with
1 mM valinomycin for 12 h to initiate Mfn2 ubiquitination, the
form factor decreased in all samples. Although there was a trend
Figure 4. Rescue of Mfn2 ubiquitination. Fibroblasts of a control, a
PINK1 and a Parkin mutant were transfected with an empty vector, a
vector containing PINK1-V5 or a vector containing FLAG-Parkin. Twenty
hours after transfection, cells were cultured under basal conditions or
treated with 1 mM valinomycin for an additional 6 h. Western blot
analysis using antibodies against V5 and FLAG showed bands of the size
of full-length/cleaved PINK1 and Parkin, respectively, in treated and
non-treated control cells after transfection, confirming the success of
the experiment (upper panel). (A) In controls, ubiquitinated Mfn2 was
detected in all three experiments after valinomycin treatment. (B) In
PINK1-mutant cells, ubiquitination of Mfn2 under stress was rescued
through overexpression of PINK1-V5 but not through overexpression of
FLAG-Parkin. (C) In Parkin-mutant fibroblasts ubiquitinated Mfn2 was
only detected after transfection with FLAG-Parkin. FL – full-length; Mfn2
– mitofusin 2; Ub-Mfn2 – ubiquitinated mitofusin 2.
doi:10.1371/journal.pone.0016746.g004
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mutant and (C) a homozygous Parkin mutant were treated with 1 mM valinomycin alone (left panel) or with 1 mM valinomycin plus 10 mM epoxomicin
(right panel). Proteins were extracted at different time points and analyzed by Western blotting. In control cells, valinomycin treatment initiated the
ubiquitination of Mfn2 after 1 h of incubation. This effect was prevented by simultaneous exposure to epoxomicin. The mitochondrial marker VDAC1
and the cytosolic marker b-actin served as loading controls. Mfn2 – mitofusin 2; Ub-Mfn2 – ubiquitinated mitofusin 2; VDAC1 – voltage-dependent
anion channel 1.
doi:10.1371/journal.pone.0016746.g005
Figure 6. Exposure to bafilomycin has no impact on Mfn2 ubiquitination. Control fibroblasts were treated with 10 nM bafilomycin alone (left
panel)orwith10 nMbafilomycin plus 1 mMvalinomycin(rightpanel).Proteinswereextracted atdifferent timepoints andanalyzedbyWesternblotting.
Bafilomycin had no effect on the Mfn2 levels and no ubiquitination was detected. When bafilomycin and valinomycin were combined, Mfn2
ubiquitination was initiated by valinomycin and not influenced by bafilomycin. In both experiments, the mitochondrial marker VDAC1 was unchanged.
b-actin served as a loading control. Mfn2 – mitofusin 2; Ub-Mfn2 – ubiquitinated mitofusin 2; VDAC1 – voltage-dependent anion channel 1.
doi:10.1371/journal.pone.0016746.g006
Mutant PINK1 and Parkin Impair Mfn Ubiquitination
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e16746towards more fragmented mitochondria in control than in mutant
cells, this difference did not reach significance (Figure 9).
Discussion
Mitochondrial dysfunction and changes in mitochondrial
morphology have long been linked to the disease mechanisms
underlying PD [2,4,5,6,7,27]. However, only recently, several
studies demonstrated that the various observed mitochondrial
phenotypes can be ascribed to one common molecular cause:
Apparently, a deficit in mitophagy leads to accumulation of
dysfunctional mitochondria in the cell [14,15,16,17]. The PD-
associated proteins PINK1 and Parkin seem to play a central role
in the initiation of mitophagy [18,19,20,28]. In a recent study, we
have established human fibroblasts with homozygous PINK1 and
Parkin mutations as a suitable model system to investigate the
PINK1/Parkin pathway [16]. Here, we expand our previous
results using these PD patient cells to characterize effects of the
PINK1/Parkin pathway on mitochondrial fusion and fission
proteins on the endogenous level.
Several studies reported that mitochondrial stress, such as
exposure to membrane potential inhibitors, initiates the PINK1/
Parkin mitophagy pathway [14,15,16,17,20,28]. Therefore, we
treated our fibroblast cell cultures with the mitochondrial
uncoupling agents valinomycin and CCCP or the superoxide
generator H2O2. All treatments resulted in decreased Mfn2 signal
in the controls but not in the mutants. However, the effect after
H2O2 incubation was the least pronounced. Moreover, high-
molecular-weight Mfn2 bands were detected in the controls,
indicative of Mfn2 poly- or multiple monoubiquitination. By
contrast, the protein levels of OPA1 and Fis1 were not altered in
mutants compared to controls under stress conditions. In
Drosophila, the mitochondrial phenotype caused by pink1 and parkin
loss-of-function mutations could at least partially be suppressed by
opa1 knockdown [8,11,12,13]. Conversely, in SH-SY5Y cells,
overexpression of OPA1 prevented changes in mitochondrial
morphology induced by PINK1 or Parkin knockdown. However,
similar to our findings, no alterations in OPA1 processing were
observed in these cells lacking PINK1 or Parkin [29]. These
apparent discrepancies could be explained by differences in OPA1
function in arthropods compared to mammals [30].
By means of immunoprecipitation, the additional anti-Mfn2
reactive bands indeed proved to represent ubiquitinated forms of
the protein. These findings are in line with recent publications
reporting that in wild-type Drosophila and SH-SY5Y cells
Mitofusins are ubiquitinated in response to mitochondrial stress.
This modification was, however, impaired in treated Parkin or
Pink1 knockdown cells [18,19,20,28]. Furthermore, studies com-
Figure 7. MG132 promotes deubiquitination of Mfn1 and Mfn2. Control fibroblasts were treated with 1 mM valinomycin. After 6 h, MG132
(final concentration 10 mM) was added to the cells. Proteins were extracted at different time points and analyzed by Western blotting. Exposure to (A)
an inhibitor of the UPS, i.e.MG132 but not to (B) DMSO alone, induced deubiquitination of both Mfn1 and Mfn2. Mfn1 – mitofusin 1; Mfn2 – mitofusin
2; VDAC1 – voltage-dependent anion channel 1.
doi:10.1371/journal.pone.0016746.g007
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that loss of parkin or pink1 increases the steady-state abundance of
mfn [18,19]. We did not detect any changes in protein levels when
monitoring Mfn2 in PINK1-o rParkin-mutant human fibroblasts
under stress conditions over time. Therefore, it is tempting to
speculate that the ‘‘increased’’ mfn levels in pink1 or parkin
knockdown flies may reflect an increase in mitochondrial
biogenesis in these mutants [17].
Of note, all experiments performed for the Mfn2 interaction
partner Mfn1 in this study indicate similar behavior of both
Mitofusins in the PINK1/Parkin pathway.
Furthermore, we were able to rescue the ubiquitination of Mfn2
when PINK1 or Parkin was re-expressed in PINK1-o rParkin-mutant
cells. In Drosophila, transgenic expression of parkin in pink1 loss-of-
function mutants markedly ameliorated all mitochondrial pheno-
types, but not vice versa, leading to the conclusion that parkin
functions downstream of pink1 [6,7,8]. However, to our surprise,
we were not able to detect ubiquitinated Mfn2 when PINK1
mutant cells were transfected with FLAG-Parkin. Given the weak
signal of ubiquitinated Mfn2 after PINK1 transfection in the Parkin-
mutant cells, a possible explanation for this discrepancy might be
that the used antibody is not sensitive enough to detect the likely
even lower levels of ubiquitinated Mfn2 in the PINK1-mutant
fibroblasts.
Whenwedetermined thesubcellularlocalization ofnon-modified
and ubiquitinated Mfn2 in control fibroblasts and SH-SY5Y cells,
allMfn2 formswereexclusively found in the mitochondrial fraction.
Ubiquitination occurred already within one hour of treatment with
valinomycin. Contrary to our expectations, inhibition of the UPS
with epoxomicin or MG132 neither increased nor preserved the
levels of ubiquitinated Mfn2 over time. Ubiquitination of Mfn2 in
control cells was apparently absent using valinomycin in combina-
tion with a proteasomal inhibitor. However, this was not explained
by interference of epoxomicin with the effect of the mitochondrial
Figure 8. Exposure to H2O2 causes ubiquitination of Mfn2. Control fibroblasts were cultured under basal conditions, treated with 1 mM
valinomycin for 6 h or with 100 mMH 2O2 for 12 h. Cells were harvested and mitochondrial and cytosolic fractions were analyzed by Western blotting.
(A) The subcellular localization of Mfn2 and Parkin was determined. Quality of cellular fractionation was confirmed using antibodies against VDAC1
and b-actin. (B) Densitometric analysis of the Western blot results revealed a significant drop in protein levels of non-modified Mfn2 (normalized
against VDAC1 expression level) in the mitochondrial fraction after valinomycin or H2O2 treatment. (C) Furthermore, both treatments caused a
significant drop in protein levels of Parkin (normalized against b-actin expression) in the cytosolic fraction. (A, right panel) A longer exposure of the
Western blot shows mitochondrial translocation of Parkin after both treatments. For quantification of protein levels, blots of three independent
experiments were evaluated. In the graphs mean intensities +/2 standard deviation are given. Cyt – cytosolic fraction; H2O2 – hydrogen peroxide; Mit
– mitochondrial fraction; Mfn2 – mitofusin 2; Ub-Mfn2 – ubiquitinated mitofusin 2; Val – Valinomycin; VDAC1 – voltage-dependent anion channel 1.
doi:10.1371/journal.pone.0016746.g008
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targeted for degradation can only enter the UPS after their
ubiquitin chain has been removed. This deubiquitination is
performed by the 19S regulatory complex of the UPS [31,32].
Epoxomicin is a potent inhibitor of the 20S proteasome subunit,
where protein degradation takes place, but does not influence the
deubiquitinase activity of the 19S particle (Figure 10) [33].
Consequently, our data suggest that, in the presence of epoxomicin
or MG132, ubiquitinated Mitofusins are solely deubiquitinated but
not degraded by the UPS leading to constant levels of non-modified
Mfn1/2in the stressed controlcells.Under stressconditionswithout
UPS inhibition, however, the turnover of ubiquitinated Mfn1/2 in
the cytosol is probably occurring too rapidly to be detected in a
fractionation experiment. In line with our hypothesis, inhibition of
lysosomal degradation did not prevent Mfn2 ubiquitination in
control fibroblasts. At first sight, there appears to be a discrepancy
between our data and a recently published report showing that the
ubiquitinated forms of Mitofusins may be preserved upon treatment
with the UPS inhibitor MG132 and the uncoupler of the
mitochondrial membrane potential CCCP [28]. However, this
can be explained by the fact that cells overexpressing Parkin were
used in that study, whereas our experimental setup was based on
endogenous levels of Parkin. It is conceivable that under conditions
of overexpressed Parkin, the balance between Parkin-mediated
ubiquitination and deubiquitination by the UPS is shifted towards
ubiquitination, thus leading to accumulation of ubiquitinated
Mitofusins in their system. Interestingly, the degradation of the
yeast Mfn1/2 homologue Fzo1 is also dependent on the UPS [34].
In a recent publication, the mitochondrial membrane potential
was identified as an important cellular parameter to differentiate
between functional and dysfunctional mitochondria. Following
fission, the refusion of daughter mitochondria requires a
membrane potential beyond a certain threshold [35]. We
hypothesize that Parkin-mediated ubiquitination and subsequent
degradation of Mfn1/2 prevents this refusion. Such isolated
dysfunctional mitochondria likely undergo mitophagy and require
both functional Parkin and PINK1. This notion is supported by
colocalization of PINK1 and partially also of Parkin with
microtubule-associated protein 1 light chain 3 (LC3), a marker
of autophagosomes [36], and by abrogation of Parkin-induced
mitophagy upon treatment with bafilomycin, a lysosomal inhibitor
[37]. For a schematic representation of the putative Parkin/
PINK1 mitophagy pathway, see Figure 11.
According to our current knowledge, mitophagy is the only
mechanism by which mitochondria are recycled [38]. Therefore,
impairment of mitophagy due to PINK1 or Parkin mutations
presumably leads to accumulation of dysfunctional mitochondria
in the cell. This scenario may be an explanation for mitochondrial
phenotypes, such as respiratory chain dysfunction [3,4,21] and
elevated mitochondrial DNA mutational load [39,40,41] which
have been observed in PINK1 or Parkin knockout models as well
as PD patients with mutations in either gene (Figure 11). In
accordance with our hypothesis, two studies in HeLa cells
provided evidence that overexpression of Parkin leads to a
significant loss of mitochondria [36,37]. However, when we
compared the expression of various mitochondrial markers in our
PINK1- and Parkin-mutant as well as control fibroblasts, no
changes indicative of differences in mitochondrial mass were
identified. A possible explanation for this discrepancy is that
mitophagy is highly selective in an endogenous model and thus
does not result in a readily observable reduction in mitochondrial
mass [38,42].
To obtain insight in the consequences of altered Mfn1/2
ubiquitination on mitochondrial morphology, we determined the
degree of branching of the mitochondrial network by measuring
the form factor [21] in PINK1-, Parkin-mutant and control cells. In
line with our qualitative observations, this quantitative assessment
showed no differences between mutant and control fibroblasts
under basal conditions. By contrast, mitochondrial branching was
found to be significantly increased in non-treated Parkin-mutants in
an earlier study on fibroblasts [21]. When we stressed the mutant
and control cells with valinomycin, the form factor decreased in all
three samples. However, we detected a trend towards more
fragmented mitochondria in control cells, supporting our hypoth-
esis. It will be interesting to see whether this trend holds up in a
larger sample of control, PINK1- and Parkin-mutant fibroblast
cultures. In the above-mentioned study [21], fibroblasts were
exposed to rotenone, an inhibitor of the respiratory chain complex
I. This treatment caused mitochondrial fragmentation in Parkin-
mutant and control cells similar to the effect of valinomycin in our
Figure 9. Branching of mitochondrial network. The mitochondrial form factor was determined in a control, a homozygous PINK1 and a
homozygous Parkin mutant. The quantification revealed no differences in mitochondrial branching between mutant and control cells under basal
conditions (light gray bars). After treatment with 1 mM valinomycin for 12 h, a decrease in branching occurred in all individuals, with the control
being most severely affected (dark gray bars). In the graph, mean form factors +/2 standard deviation are given.
doi:10.1371/journal.pone.0016746.g009
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were detected between the investigated groups after exposure to
mitochondrial stress [21]. Since mitochondrial fusion and fission
are transient events, dynamic quantification methods would be
useful to determine the impact of PINK1 and Parkin mutations on
mitochondrial morphology.
Confirming the results from arthropod studies and expanding
on our previous findings, we showed that endogenous mutations in
PINK1 and Parkin impair ubiquitination of mitofusins in human
fibroblasts. In addition, our results imply that the UPS is involved
in the degradation of Mitofusins under mitochondrial stress
conditions.
Materials and Methods
Ethics statement
Written informed consent was obtained from all study
participants and the study was approved by the local ethics
committee of the University of Lu ¨beck.
Tissue culture
Human dermal primary fibroblasts used in the present study
were described before [16,22,43]. Fibroblasts and commercially
available SH-SY5Y were cultured in high glucose Dulbecco’s
Modified Eagle’s Medium supplemented with 10% fetal bovine
serum and 1% penicillin–streptomycin (all PAA) at 37uC, 5%
CO2. In all assays, fibroblast passage numbers were matched
(,10).
To induce mitochondrial stress, fibroblasts and SH-SY5Y cells
were treated with the potassium ionophore valinomycin (1 mM,
Sigma), the protonophore CCCP (10 mM, Sigma) or with the
superoxide generator H2O2 (100 mM, Sigma). For inhibition of the
proteasome system epoxomicin (10 mM, Sigma) or MG132
(10 mM, Sigma) were used. To inhibit the acidification of
lysosomes bafilomycin was employed (10 nM, Sigma).
Mitochondrial preparation
Mitochondria were isolated from fibroblasts as previously
described [43]. In brief, cells were harvested and homogenized
Figure 10. Possible scenario of Mfn1/2 deubiquitination and degradation at the UPS. Under valinomycin stress, Mitofusins are
ubiquitinated by Parkin. Poly-ubiquitinated Mitofusins are subsequently recognized by the intrinsic ubiquitin-binding activity of the 19S particle of
the 26S proteasome. At the 19S regulatory complex the ubiquitin chain is disassembled, and the substrate is unfolded before it can enter the cavity of
the 20S subunit where proteolysis takes place [31]. Simultaneous treatment with epoxomicin (or MG132) inhibits the degradation function of the 20S
core particle but does not influence the deubiquitylase activity of the 19S subunit. Consequently, poly-ubiquitinated Mitofusins are deubiquitinated
at the proteasome but cannot be degraded. Mfn1/2 – mitofusin 1/2; Ub – ubiquitin; UPS – ubiquitin proteasome system.
doi:10.1371/journal.pone.0016746.g010
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EDTA, pH 7.4. After that, nuclei and unbroken cells were
removed by centrifugation at 1,5006g for 20 min. The superna-
tant containing intact mitochondria was transferred into a new
tube and centrifuged at 12,0006g for 10 min. Supernatant
(‘‘cytosolic fraction’’) was transferred into another new tube and
the mitochondria-enriched pellet (‘‘mitochondrial fraction’’) was
dissolved in radioimmunoprecipitation assay (RIPA) buffer
containing a cocktail of protease and phosphatase inhibitors
(Roche Diagnostics).
Cytoplasmic fractions were concentrated by using centricon
YM-10 devices (Millipore) according to the manufacturer’s
instructions. Proteins of the mitochondrial and cytoplasmic
fractions were separated by sodium dodecyl sulfate polyacrylamide
Figure 11. Scheme summarizing PINK1’s and Parkin’s putative function in mitophagy. By means of fission, mitochondria are randomly
divided. Damaged mitochondria can be distinguished from functional mitochondria, for instance, by a difference in membrane potential.
Dysfunctional mitochondria with low membrane potential are detected by PINK1, which recruits Parkin. Next, Parkin ubiquitinates Mfn1/2 which
localize to the outer mitochondrial membrane. Subsequently, ubiquitinated Mitofusins are degraded by the UPS, preventing fusion of dysfunctional
with functional mitochondria. By this, dysfunctional mitochondria are selected out from the general pool of mitochondria and subsequently undergo
mitophagy. Dy – mitochondrial membrane potential; Mfn1/2 – mitofusin 1/2; PINK1 – PTEN-induced putative kinase 1; Ub-Mfn1/2 – ubiquitinated
mitofusin 1/2; UPS – ubiquitin proteasome system.
doi:10.1371/journal.pone.0016746.g011
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analysis using appropriate antibodies.
Protein extraction
Proteins were extracted using RIPA buffer containing 0.1%
SDS (50 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% DOC, 1%
NP-40 and 0.1% SDS). Cells or mitochondria-enriched pellets
were dissolved in the appropriate amount of buffer and incubated
on ice for 30 min. After that, the lysates were centrifuged at
16,0006g for 20 min at 4uC. The supernatant was transferred into
a new tube and used for Western blotting.
Immunoprecipitation
Fibroblasts plated in 15 cm Petri dishes were treated with 1 mM
valinomycin. Next, cells were harvested and resuspended in 1 ml
of lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.6, 1% NP-
40, 0.1% SDS, protease inhibitor cocktail (Roche Diagnostics)).
Lysates were incubated on ice for 30 min and cleared by
centrifugation at 13,0006g for 10 min. Samples were equalized
for the protein concentration and incubated with 5 ml of anti-Mfn2
antibody overnight on a rotator. Fifty ml of washed protein G
agarose beads (Roche Diagnostics) were added to the samples.
This was followed by incubation for 2 h on a rotator. Next, the
beads were pelleted by centrifugation and the supernatant was
discarded. The beads were washed three times with lysis buffer
followed by resuspension into 26loading buffer (Invitrogen) and
incubation at 95uC for 5 min. After centrifugation, the superna-
tant was analyzed by Western blotting.
Western blot analysis
SDS PAGE was performed using NuPAGE 4–12% Bis-Tris gels
(Invitrogen). After electrophoresis, proteins were transferred to the
nitrocellulose membrane (Protran) and probed with antibodies
raised against Mfn1 (Abcam, # ab60939), Mfn2 (Abcam, #
ab56889), b-actin (Sigma, # A 5316), VDAC1 (Abcam, #
ab14734), OPA1 (Abcam, # ab42364), Fis1 (Alexis Biochemicals,
# ALX-210-907), FLAG M2 (Sigma, # F 1804), V5 (Invitrogen,
# R960-25) and ubiquitin (Boston Biochem, # AB-001). All
Western blot analyses were performed in triplicates for all
available mutants (PINK1: p.Q456X and p.V170G; Parkin:
p.V324fsX434 and p.R245fsX253) and two controls, and
representative blots are shown in the figures. For densitometric
analyses TotalLab software (Nonlinear Dynamics) was used.
Transient transfection
Fibroblasts were transiently transfected with pcDNA3.1 V5/His
(Invitrogen) containing full-length wild-type PINK1 cDNA (FL
PINK1). For overexpression of Parkin, N-terminally FLAG-tagged
full-length Parkin cDNA was cloned in pcDNA3.1 (Invitrogen’s
modified vector lacking V5/His tags). For Mfn1 or Mfn2 knock-
down, Hs_MFN1_5 or Hs_MFN2_5 validated siRNAs (both
Qiagen) (final concentration 50 nM) were used and scramble
siRNA (Silencer negative control 1 siRNA [Ambion]) (final
concentration 50 nM) with no known mammalian homology
served as negative control. All transfections of fibroblasts were
performed using the Nucleofector Device (Lonza).
Analysis of the mitochondrial membrane potential
The mitochondrial membrane potential was analyzed using
5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzimidazolylcarbocya-
nine iodide (JC-1; Invitrogen) according to the manufacturer’s
protocol [44].
Assessment of mitochondrial branching
The mitochondrial network in fibroblasts was stained with an
anti-GRP75 antibody (Abcam, # ab53098) in combination with
the zenon immunolabelling kit (Invitrogen) according to the
manufacturer’s protocol.
The morphology of the mitochondrial network was investigated
using a fluorescence microscope equipped with an ApoTome and
AxioVision software (all Zeiss). By means of ImageJ 1.42, raw
images were binarized, mitochondrion area and outline were
measured and the form factor was calculated [21]. Images of at
least five randomly selected cells per individual were analyzed
under basal conditions and after treatment with valinomycin.
Statistical analysis
For evaluation of the impact of stress on cells, a paired Student’s
t-test was used to determine differences before and after treatment.
All p-values below 0.05 were considered indicative of a significant
difference between measurements and are shown by an asterisk.
Supporting Information
Figure S1 Protein levels of Mfn1 after valinomycin
treatment. (A) Fibroblasts from a healthy control, a homozygous
PINK1 mutant and a homozygous Parkin mutant were cultured
under basal conditions or treated with 1 mM valinomycin for 12 h.
The protein levels of Mfn1 were investigated by means of Western
blotting. Valinomycin exposure caused a drop in Mfn1 levels in
controls, but not in PINK1-o rParkin-mutant cells. b-actin served as
a loading control. (B) Mutant cells were transfected with scrambled
siRNA, Mfn1 siRNA, Mfn2 siRNA or a combination of Mfn1 and
Mfn2 siRNA for 40 h. Western blot analysis was performed with an
antibody against Mfn1. The Mfn1 levels decreased only when Mfn1
siRNA was employed, confirming the specificity of the anti-Mfn1
antibody used in our study. Mfn1 – mitofusin 1; Mfn2 – mitofusin 2.
(TIFF)
Figure S2 Protein levels of Mfn2 after CCCP treatment.
Fibroblasts from two healthy controls, two homozygous PINK1
mutants and one homozygous Parkin mutant were cultured under
basal conditions or treated with 10 mM CCCP for 12 h. The
protein levels of Mfn2 were investigated by means of Western
blotting. CCCP exposure caused a decrease in Mfn2 levels in
controls, but not in PINK1-o rParkin-mutant cells. b-actin served as
a loading control. CCCP – cyanide m-chlorophenylhydrazone;
Mfn2 – mitofusin 2.
(TIFF)
Figure S3 Immunoprecipitation with antibodies against
Mfn2. Control, PINK1- and Parkin-mutant cells were treated with
1 mM valinomycin for 12 h. Cells were harvested and whole cell
lysates were used for immunoprecipitation with antibodies against
GRP75 or Mfn2. The resulting precipitates were analyzed by
Western blotting using antibodies against Mfn2 and GRP75. An
Mfn2 immunoreactive band of higher molecular weight was
detected only in controls but not in either of the mutants.
Immunoprecipitation with an antibody against the mitochondrial
marker GRP75 served as a negative control. GRP75 – glucose-
regulated protein 75; IgG – immunoglobulin G; Mfn2 – mitofusin
2; Ub-Mfn2 – ubiquitylated mitofusin 2.
(TIFF)
Figure S4 Mitochondrial localization of ubiquitylated
Mfn1 and Mfn2 after valinomycin treatment. Control
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PLoS ONE | www.plosone.org 11 March 2011 | Volume 6 | Issue 3 | e16746fibroblasts were cultured under basal conditions or treated with
1 mM valinomycin for 6 h. Cells were harvested, proteins of
mitochondrial and cytosolic fractions were loaded on two SDS-
PAGE gels and analyzed by Western blotting. The subcellular
localizations of Mfn1 and Mfn2 were determined. Quality of
cellular fractionation was confirmed using antibodies against
VDAC1 and b-actin. The ubiquitylated forms of Mfn1 and Mfn2,
which were observed only after valinomycin stress, are exclusively
found in the mitochondrial fraction. Cyt – cytosolic fraction; Mit –
mitochondrial fraction; Mfn1 – mitofusin 1; Mfn2 – mitofusin 2;
VDAC1 – voltage-dependent anion channel 1.
(TIFF)
Figure S5 Mitochondrial localization of ubiquitylated
Mfn2 after valinomycin treatment in SH-SY5Y cells. SH-
SY5Y cells were cultured under basal conditions or treated with
valinomycin for 6 h. Cells were harvested and mitochondrial and
cytosolic fractions were analyzed by Western blotting. The
subcellular localization of Mfn2 was determined. Quality of
cellular fractionation was confirmed using antibodies against
VDAC and b-actin. The ubiquitylated forms of Mfn2, which were
observed only after valinomycin stress, are exclusively found in the
mitochondrial fraction. Mfn2 – mitofusin 2; Ub-Mfn2 –
ubiquitylated mitofusin 2; VDAC1 – voltage-dependent anion
channel 1.
(TIFF)
Figure S6 Ubiquitylation of Mfn2 occurs within 1 h of
valinomycin treatment. Fibroblasts from a healthy control
were treated with 1 mM valinomycin alone (left panel) or with
1 mM valinomycin plus 10 mM MG132 (right panel). Proteins
were extracted at different time points and analyzed by Western
blotting. Valinomycin treatment initiated the ubiquitylation of
Mfn2 after 1 h of incubation. This effect was prevented by
simultaneous exposure to MG132. b-actin served as a loading
control. An unspecific band is marked by an asterisk. Mfn2 –
mitofusin 2; Ub-Mfn2 – ubiquitylated mitofusin 2.
(TIFF)
Figure S7 Treatment with valinomycin alone or in
combination with epoxomicin causes a drop in mito-
chondrial membrane potential. Control fibroblasts were
incubated with either 1 mM valinomycin alone or with 1 mM
valinomycin plus 10 mM epoxomicin. The membrane potential
was measured at different time points and corrected for protein
concentration. Exposure to the proteasome inhibitor epoxomicin
did not influence the membrane potential over time. In the graph
mean values +/2 standard deviation of three independent
experiments are given. Dy – mitochondrial membrane potential.
(TIFF)
Figure S8 No accumulation of Mfn2 after exposure to
epoxomicin. Control fibroblasts were treated with 10 mM
epoxomicin. Proteins were extracted at different time points and
analyzed by Western blotting. Exposure to the proteasome
inhibitor epoxomicin did not affect the expression of Mfn2 over
time. The mitochondrial marker VDAC1 and the cytosolic marker
b-actin served as loading controls. Mfn2 – mitofusin 2; VDAC1 –
voltage-dependent anion channel 1.
(TIFF)
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